Lucent Diagnostics and Tempus AI partner to expand access to Alzheimer’s blood biomarker testing
Collaboration integrates LucentAD Complete into AI‑driven clinical workflows to support earlier detection and treatment decisions
8 May 2026Industry news
Lucent Diagnostics, a brand of Quanterix Corporation, has announced a collaboration with Tempus AI Inc., a technology company advancing the use of artificial intelligence in precision medicine, to broaden access in the United States to LucentAD® Complete, a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease.
Under this agreement, Tempus AI will develop a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, and neurologists will be able to order LucentAD Complete directly through the Tempus clinical ordering platform.
Addressing the Alzheimer’s disease diagnosis and treatment gap
More than 7 million Americans are living with Alzheimer’s disease, yet only a small fraction are evaluated for eligibility for approved treatments. The new collaboration between Lucent Diagnostics and Tempus AI aims to narrow this gap by embedding clinical guideline-directed patient identification and blood-based biomarker testing options into the clinical decision-making workflows used by neurologists.
By integrating LucentAD Complete into Tempus Next, the collaboration is designed to support earlier and more accurate identification of amyloid-positive patients who may be candidates for approved Alzheimer’s disease therapies. This approach seeks to make blood-based biomarker testing a routine part of neurology practice, while minimizing additional workload for healthcare providers.
Integrating LucentAD Complete into Tempus Next workflows
Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and provides healthcare professionals with actionable insights aligned with clinical guidelines at the point of care. As part of the agreement, Tempus AI will build a Tempus Next care gap program specifically focused on Alzheimer’s disease blood-based biomarker testing.
Within this program, LucentAD Complete, a multi-biomarker blood test, will be available for neurologists to order through the Tempus clinical ordering platform. Clinicians will have the option to request LucentAD Complete via existing electronic health record (EHR) integrations, helping to streamline ordering and reduce barriers to access.
Everett Cunningham, CEO of Quanterix, said, “This collaboration represents an important step toward ensuring blood-based Alzheimer’s biomarker testing becomes part of routine clinical practice – without placing additional burden on providers.”
"By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. As we look to advance precision health through high-sensitivity biomarker innovation, collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions,” he added.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How does the collaboration between Lucent Diagnostics and Tempus AI aim to improve Alzheimer’s disease diagnosis in the United States?
The collaboration between Lucent Diagnostics, a brand of Quanterix Corporation, and Tempus AI Inc. is designed to broaden access in the United States to LucentAD® Complete, a novel blood-based biomarker panel for Alzheimer’s disease. Under the agreement, Tempus AI will develop a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, enabling neurologists to order LucentAD Complete directly through the Tempus clinical ordering platform.
By embedding clinical guideline-directed patient identification and blood-based biomarker testing options into neurology workflows, the partnership aims to support earlier and more accurate identification of amyloid-positive patients who may be candidates for approved Alzheimer’s disease therapies.
What role does the Tempus Next AI-enabled care pathway intelligence platform play in integrating LucentAD Complete into neurology practice?
Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and provides healthcare professionals with actionable insights aligned with clinical guidelines at the point of care.
As part of the collaboration, Tempus AI will build a Tempus Next care gap program specifically focused on Alzheimer’s disease blood-based biomarker testing. Within this program, LucentAD Complete, a multi-biomarker blood test, will be available for neurologists to order through the Tempus clinical ordering platform, including via existing electronic health record (EHR) integrations.
This integration is intended to streamline ordering, reduce barriers to access, and make blood-based biomarker testing a routine part of neurology practice while minimizing additional workload for providers.
How does LucentAD Complete support precision medicine and precision health in Alzheimer’s disease care?
LucentAD Complete is a novel, multi-biomarker blood test designed to improve detection accuracy for Alzheimer’s disease by helping identify amyloid-positive patients who may be eligible for approved therapies.
According to Everett Cunningham, CEO of Quanterix, integrating LucentAD Complete into the Tempus ordering workflow is intended to make blood-based Alzheimer’s biomarker testing part of routine clinical practice without adding burden to providers.
The partnership between Lucent Diagnostics and Tempus AI reflects a shared focus on advancing precision health and precision medicine through high-sensitivity biomarker innovation and on streamlining the diagnostic journey to support earlier, more confident clinical decisions in Alzheimer’s disease.